Home › Trials › NCT07243132

Long-term survivors of metastatic lung cancer: health, quality of life, and needs

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (LUNGEVITY STUDY)

Observational Groupe Francais De Pneumo-Cancerologie · NCT07243132

This project will follow people who have lived at least three years with metastatic lung cancer and are no longer on cytotoxic chemotherapy to see what their health, quality of life, and social needs are.

Quick facts

Study typeObservational
Enrollment1000 (estimated)
Ages18 Years and up
SexAll
SponsorGroupe Francais De Pneumo-Cancerologie Academic / other
Drugs / interventionschemotherapy
Locations46 sites (Aix-en-Provence and 45 other locations)
Trial IDNCT07243132 on ClinicalTrials.gov

What this trial studies

This is a prospective observational follow-up of adults in France who have lived three or more years after a diagnosis of metastatic NSCLC or SCLC and are not receiving cytotoxic chemotherapy. Participants complete standardized questionnaires (HAD, QLQ-LC13, AMU) at inclusion, at 6 and 12 months, and then annually up to five years while clinical data are collected during routine visits. The study will record treatment history, new medical conditions (including cardiovascular disease, diabetes, and second cancers), socioeconomic impacts, and return-to-work outcomes. Data are collected at participating French centers to characterize long-term responder needs and inform survivorship care.

Who should consider this trial

Good fit: Adults in France with stage III or IV metastatic NSCLC or SCLC who have survived at least three years since diagnosis, are not on cytotoxic chemotherapy, have French-language comprehension, and are covered by French national or third-party health insurance.

Not a fit: Patients currently receiving cytotoxic chemotherapy, those with insufficient French comprehension, those under legal guardianship, or those unable to complete follow-up are excluded and unlikely to benefit from the study's findings.

Why it matters

Potential benefit: If successful, the project could identify unmet medical and social needs and guide better follow-up, supportive care, and return-to-work programs for long-term metastatic lung cancer survivors.

How similar studies have performed: There is some survivorship research, but few studies have specifically focused on long-term responders to metastatic lung cancer, so this addresses a relatively under-studied area.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient over 18 years old
* Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance).
* Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance

Exclusion Criteria:

* Difficulties for understanding French
* Patients undergoing treatment with cytotoxic chemotherapy
* Patients under legal guardianship, under curatorship or tutorship
* Insufficient cognitive capacity to answer questions
* Inability to obtain data collection (lost to follow-up, patient's refusal for data collection)
* Patients refusing the collection of their data (an information sheet will be provided)

Where this trial is running

Aix-en-Provence and 45 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Metastatic Lung CancerMetastatic NSCLCMetastatic Small Cell Lung Cancerlong-terms respondersMestastatic Lung CancerMetastatic small cell lung cancer
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.